TY - JOUR
T1 - Apomorphine SC treatment in parkinsonian patients with long term L-DOPA syndrome during L-DOPA drug holiday
AU - Scarzella, L.
AU - Delsedime, M.
AU - Ferrero, B.
AU - Giangrandi, C.
AU - Priano, L.
AU - Rizzone, M.
AU - Bergamasco, B.
PY - 1995
Y1 - 1995
N2 - The Long Term Dopa Syndrome (LTDS) is one of the main problems in the management of advanced parkinsonian patients. A transient L-Dopa withdrawal (Drug Holiday, DH) can be useful to improve the drug response after DH, even if this approach presents risks due to patient akinesia. We tried to verify if Apomorphine sc administration during DH (DH with Apomorphine, DHA) can: a) reduce the risks connected with DH; b) maintain the benefits of DH; c) standardize the duration of DH. Twenty-five parkinsonian patients with LTDS were treated with Apomorphine sc during DH (14 days). No patient had any severe side effects. The follow-up at 180 days, conducted using the Unified Parkinson's Disease Rating Scale, demonstrated a significant improvement in the clinical conditions of about 70% of the patients, allowing a 27.1% reduction in daily L-dopa dosage. DHA can represent a valid therapeutical approach for parkinsonian patients with LTDS.
AB - The Long Term Dopa Syndrome (LTDS) is one of the main problems in the management of advanced parkinsonian patients. A transient L-Dopa withdrawal (Drug Holiday, DH) can be useful to improve the drug response after DH, even if this approach presents risks due to patient akinesia. We tried to verify if Apomorphine sc administration during DH (DH with Apomorphine, DHA) can: a) reduce the risks connected with DH; b) maintain the benefits of DH; c) standardize the duration of DH. Twenty-five parkinsonian patients with LTDS were treated with Apomorphine sc during DH (14 days). No patient had any severe side effects. The follow-up at 180 days, conducted using the Unified Parkinson's Disease Rating Scale, demonstrated a significant improvement in the clinical conditions of about 70% of the patients, allowing a 27.1% reduction in daily L-dopa dosage. DHA can represent a valid therapeutical approach for parkinsonian patients with LTDS.
UR - http://www.scopus.com/inward/record.url?scp=0028971701&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028971701&partnerID=8YFLogxK
M3 - Article
C2 - 8748622
AN - SCOPUS:0028971701
SP - 163
EP - 170
JO - Journal of Neural Transmission, Supplement
JF - Journal of Neural Transmission, Supplement
SN - 0303-6995
IS - 45
ER -